Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever
George M. Warimwe, Joseph Gesharisha, B. Veronica Carr, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 107

Showing 1-25 of 107 citing articles:

Bat-borne virus diversity, spillover and emergence
Michael Letko, Stephanie N. Seifert, Kevin J. Olival, et al.
Nature Reviews Microbiology (2020) Vol. 18, Iss. 8, pp. 461-471
Open Access | Times Cited: 437
Emerging Concepts and Technologies in Vaccine Development
Morgan Brisse, Sophia M. Vrba, Natalie M. Kirk, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 256
Rift Valley fever: biology and epidemiology
Daniel Wright, Jeroen Kortekaas, Thomas A. Bowden, et al.
Journal of General Virology (2019) Vol. 100, Iss. 8, pp. 1187-1199
Open Access | Times Cited: 152
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
Shen Wang, Bo Liang, Weiqi Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 91
Effects of climate change on the occurrence and distribution of livestock diseases
Bernard Bett, P.N. Kiunga, John Gachohi, et al.
Preventive Veterinary Medicine (2016) Vol. 137, pp. 119-129
Closed Access | Times Cited: 159
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
Naif Khalaf Alharbi, Eriko Padron-Regalado, Craig Thompson, et al.
Vaccine (2017) Vol. 35, Iss. 30, pp. 3780-3788
Open Access | Times Cited: 158
A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
Mohamed Osman, Anoop Mistry, Ada Keding, et al.
PLoS neglected tropical diseases (2017) Vol. 11, Iss. 5, pp. e0005527-e0005527
Open Access | Times Cited: 141
Current Status of Rift Valley Fever Vaccine Development
Bonto Faburay, A. Desirée LaBeaud, D. Scott McVey, et al.
Vaccines (2017) Vol. 5, Iss. 3, pp. 29-29
Open Access | Times Cited: 123
Identification and Immunogenicity of African Swine Fever Virus Antigens
Christopher L. Netherton, Lynnette C. Goatley, Ana Luísa Reis, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 115
Rift Valley Fever
Amy L. Hartman
Clinics in Laboratory Medicine (2017) Vol. 37, Iss. 2, pp. 285-301
Open Access | Times Cited: 103
The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses
Longping V. Tse, Rita M. Meganck, Rachel L. Graham, et al.
Frontiers in Microbiology (2020) Vol. 11
Open Access | Times Cited: 102
Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels
Naif Khalaf Alharbi, Ibrahim Qasim, Abdulrahman Almasoud, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 82
Rift Valley Fever – epidemiological update and risk of introduction into Europe
Søren Saxmose Nielsen, Julio Álvarez, Dominique Bicout, et al.
EFSA Journal (2020) Vol. 18, Iss. 3
Open Access | Times Cited: 78
Rift Valley fever – a growing threat to humans and animals
Małgorzata Kwaśnik, Wojciech Rożek, J. Rola
Journal of Veterinary Research (2021) Vol. 65, Iss. 1, pp. 7-14
Open Access | Times Cited: 61
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Lynda Coughlan, Eric J. Kremer, Dmitry M. Shayakhmetov
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1822-1849
Open Access | Times Cited: 45
Vaccine development: Current trends and technologies
Renu Poria, Deepak Kala, Rupak Nagraik, et al.
Life Sciences (2023) Vol. 336, pp. 122331-122331
Closed Access | Times Cited: 28
Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model
Vincent J. Munster, Daniel Wells, Teresa Lambe, et al.
npj Vaccines (2017) Vol. 2, Iss. 1
Open Access | Times Cited: 86
Recent advances in viral vectors in veterinary vaccinology
Michael D. Baron, Munir Iqbal, Venugopal Nair
Current Opinion in Virology (2018) Vol. 29, pp. 1-7
Open Access | Times Cited: 65
The One Health Approach is Necessary for the Control of Rift Valley Fever Infections in Egypt: A Comprehensive Review
Mohamed Fawzy, Yosra A. Helmy
Viruses (2019) Vol. 11, Iss. 2, pp. 139-139
Open Access | Times Cited: 64
A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters
Neeltje van Doremalen, Teresa Lambe, Sarah Sebastian, et al.
PLoS neglected tropical diseases (2019) Vol. 13, Iss. 6, pp. e0007462-e0007462
Open Access | Times Cited: 63
An Overview of Rift Valley Fever Vaccine Development Strategies
Paul Kato Kitandwe, Paul F. McKay, Pontiano Kaleebu, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1794-1794
Open Access | Times Cited: 35
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Pedro M. Folegatti, Daniel Jenkin, Susan Morris, et al.
Vaccine (2022) Vol. 40, Iss. 35, pp. 5248-5262
Open Access | Times Cited: 29
Immunopathogenesis of Nipah Virus Infection and Associated Immune Responses
Brent Brown, Tanya Gravier, Ingo Fricke, et al.
Immuno (2023) Vol. 3, Iss. 2, pp. 160-181
Open Access | Times Cited: 21
Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates
Cigdem Alkan, Eduardo Jurado-Cobena, Tetsuro Ikegami
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 21
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Daniel Jenkin, Daniel Wright, Pedro M. Folegatti, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 8, pp. 956-964
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top